Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dabocemagene autoficel - Fibrocell Science

Next Previous
Drug Profile

Dabocemagene autoficel - Fibrocell Science

Alternative Names: D-Fi; FCX-007; Fibroblast epidermolysis bullosa cell therapy -Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica cell therapy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica gene thearpy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa gene therapy -Fibrocell/Intrexon; Fibroblast-RDEB-cell-therapy-Fibrocell/Intrexon; Fibroblast-RDEB-gene-therapy-Fibrocell/Intrexon; Genetically modified human dermal fibroblast-collagen VII; Genetically-Modified Autologous Human Dermal Fibroblasts; GM-HDF-COL7

Latest Information Update: 12 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fibrocell Science
  • Developer Fibrocell Science; Precigen Inc
  • Class Cell therapies; Fibroblast cell therapies; Gene therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements; Collagen type VII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epidermolysis bullosa dystrophica

Most Recent Events

  • 07 Dec 2022 Dabocemagene autoficel is still in phase III trials for Epidermolysis bullosa in USA (NCT04213261)
  • 18 Apr 2022 Castle Creek Biosciences terminates phase I trial in Epidermolysis bullosa dystrophica in USA (NCT02810951)
  • 25 Jan 2022 Castle Creek Biosciences plans to submit Clinical Trial Application to USA FDA for phase III trial for epidermolysis bullosa dystrophica (Paragon Biosciences pipeline, January 2022) (Castle Creek Biosciences pipeline, January 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top